Paul Hudson, Sanofi CEO (Eric Piermont/AFP via Getty Images)
April 27, 2023 07:24 AM EDT
R&D

Sanofi scraps top­i­cal BTK drug from $3.7B Prin­cip­ia buy­out

Amber Tong

Sanofi is sweep­ing a can­di­date from its $3.7 bil­lion Prin­cip­ia buy­out out of the pipeline, rais­ing new ques­tions about the BTK fran­chise.

The com­pa­ny is …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Why did Eli Lil­ly ask a pa­tient on a com­pound­ed GLP-1 drug for their med­ical in­for­ma­tion?

Biotech VC firm out­lines plans for $100M fund

No­vo says its CB1 drug helped shed weight, but ef­fi­ca­cy and safe­ty ques­tions re­main

FTC to sue ma­jor PBMs over in­sulin re­bates, claim­ing they in­flat­ed pa­tient cost

FDA OKs the first-ever self-ad­min­is­tered vac­cine, for flu

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times